Tofacitinib - Juvenile Idiopathic Arthritis

You are here : Home > Formulary Search > Tofacitinib - Juvenile Idiopathic Arthritis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red

Formulations :

Tablets

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

Guidelines

ICB

NHSE

NICE

SPC

Restrictions / Comments :

Important

NHS England are the responsible commissioners for people being treated in the childrens service

ICBs are the responsible commissioners for people being treated in the adults service.

Documentation

NICE Technology Appraisal

NICE TA735 -Tofacitinib for treating juvenile idiopathic arthritis - October 2021

PAD Profile

ChemicalSubstance :

Tofacitinib

Indication :

Juvenile Idiopathic Arthritis

Group Name :

Keywords :

JIA, NICE, NHS England, pain, SERMOG, South East Region Medicines Optimisation Group, polyarticular, polyarticular-onset, polyarticular-course, extended oligoarticular JIA, ICB

Brand Names Include :

RoActemra, Tyenne, Avtozma

Important Information :

Latest Additions Date From :

01 Oct 2025

Latest Additions Date To :

31 Oct 2025

Guidelines :

Juvenile Idiopathic Arthritis

Supporting Documents :

Committee Recommendations (0)

No records returned.

Other Indications

Below are listed other indications that Tofacitinib is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Juvenile Idiopathic Arthritis.